Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hexyl aminolevulinate - Photocure

Drug Profile

Hexyl aminolevulinate - Photocure

Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; APL-1702; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206

Latest Information Update: 28 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PhotoCure
  • Developer Ipsen; Juno Pharmaceuticals; Photocure
  • Class Amino acids; Antineoplastics; Esters; Imaging agents; Levulinic acids; Oxidants; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer
  • Phase III Cervical intraepithelial neoplasia
  • Discontinued Colorectal cancer

Most Recent Events

  • 26 Jan 2021 Hexyl aminolevulinate licensed to Asieris Pharmaceuticals for registration and commercialisation in China and Taiwan for Bladder cancer
  • 05 Oct 2020 PhotoCure has patent protection for hexyl aminolevulinate in Europe
  • 01 Sep 2020 Phase-III clinical trials in Cervical intraepithelial neoplasia in USA, Germany, China, Romania, Hungary, Russia, Ukraine (Topical) in September 2020 (NCT04484415) (EudraCT2020-001342-19)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top